Neurocrine Biosciences (NBIX) Cash & Current Investments (2010 - 2026)

Neurocrine Biosciences has reported Cash & Current Investments for 17 years, with the latest figure at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 39.5% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 39.5% YoY), and the FY2025 full-year result was $1.5 billion, up 37.57% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $1.3 billion, down from $1.5 billion in the prior quarter.
• The five-year high for Cash & Current Investments was $1.5 billion in Q4 2025, with the low at $648.3 million in Q2 2022.
• Historically, Cash & Current Investments has averaged $1.0 billion across 5 years, with a median of $1.0 billion in 2024.
• Annual changes were most pronounced in 2022 — Cash & Current Investments decreased 26.74% — and 2023, when it surged 50.66%.
• Neurocrine Biosciences' Cash & Current Investments stood at $997.1 million in 2022, then climbed by 4.26% to $1.0 billion in 2023, then rose by 3.51% to $1.1 billion in 2024, then surged by 37.57% to $1.5 billion in 2025, then declined by 11.09% to $1.3 billion in 2026.
• The last three Cash & Current Investments figures came in at $1.3 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.